Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 10fludarabine 8Dexamethasone 8Lenalidomide 6Bortezomib 5Granulocyte Colony-Stimulating Factor 468Ga-pentixafor 4Melphalan 3Filgrastim 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2tocilizumab 1selinexor 1ruxolitinib 1pomalidomide 1pembrolizumab 1methyl prednisolonate 1ixazomib 1ioversol 1inebilizumab 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Hydroxychloroquine × Plasma cell × Clear all
NCT01396200 2013-02-26

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
6 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡